Thanks SOT,
I appreciate the clarification. Your disclosure of the Janssen presentation has been very exciting, assuming of course that the academic/biotech consortium refers to Telethon Institute/Phylogica.
Do you have any background information as to the importance of the work on Centyrins by the research team at Janssen. Some projects would have a high company profile while others are relatively unimportant. It would appear, however, that drug conjugates is a relatively hot field e.g. the deal between Roche and Molecular Partners.
Wayne.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.000(0.00%) |
Mkt cap ! $787.4M | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.39 | $1.33 | $54.32K | 40.06K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2888 | $1.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 4256 | 3 |
View Market Depth
| Last trade - 11.09am 21/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |